SMARCA4 and non-small cell lung carcinoma: In the analysis by Velut et al., NSCLC patients with SMARCA4 mutations (N = 7) did worse than WT (N = 70), independent of whether they received ICI therapy or not (HR: 3.2; p = 0.006) [29].